FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Albiglutide (Tanzeum) Injection
Status: Discontinuation
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

GlaxoSmithKline (New 12/21/2017)

Company Contact Information:
888-825-5249

Presentation Posting Date Related Information
30-mg single-dose pen; carton of 4 (NDC 0173-0866-35) 12/21/2017 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately June 30, 2018.
50-mg single-dose pen; carton of 4 (NDC 0173-0867-35) 12/21/2017 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately July 31, 2018.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English